Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

Abstract INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1-3] It is unknown, however, if TDF has an intrinsic lipid-lowering effect or such findings are due to the addition or removal of other offending agents or other reasons. MATERIALS AND METHODS: RESULTS: 46 subjects with a median age of 43 (40-48) years were enrolled in the study: 70% were male, 56% received DRV/r and 44% LPV/r. One subject withdrew the study voluntarily at week 4 and another one interrupted due to diarrhoea at week 24. Treatment with TDF/FTC decreased total, LDL and HDL-cholesterol from 235.9 to 204.9 (p<0.001), 154.7 to 127.6 (p<0.001) and 50.3 to 44.5 mg/dL (p<0.001), respectively. In comparison, total, LDL and HDL-cholesterol levels remained stable during placebo exposure. Week 12 total cholesterol (p<0.001), LDL-cholesterol (p<0.001) and HDL-cholesterol (p=0.011) levels were significantly lower in TDF/FTC versus placebo. Treatment with TDF/FTC reduced the fraction of subjects with abnormal fasting total-cholesterol (≥200 mg/dL) from 86.7% to 56.8% (p=0.001) and LDL-cholesterol (≥130 mg/dL) from 87.8% to 43.9% (p<0.001), which was not observed with placebo. There were no virological failures, and CD4 and triglyceride levels remained stable regardless of exposure. CONCLUSION: Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attributable to TDF.

Parametrització d’un procés basat en marro de cafè pel tractament d’aigües residuals que contenen Cr(VI)

Aquest projecte forma part d’un estudi sobre l’eliminació de metalls pesants utilitzant com aadsorbents residus d’indústries agroalimentàries, que des de fa uns quants anys està duent aterme el grup de Metalls i Medi Ambient (MiMA) del Departament d’Enginyeria Química,Agrària i Tecnologia Agroalimentària de la Universitat de Girona. L’objecte del treball és parametritzar un procés basat en marro de cafè que inclouetapes de reducció/adsorció i precipitació per al tractament d’aigües residuals quecontenen Cr(VI) i altres metalls. La parametrització permetrà conèixer en quinmoment s’ha assolit la reducció total del Cr(VI) en la primera etapa del tractament perpoder passar a una segona etapa d’eliminació de la resta dels metalls presents en solució

Maneig i compliment terapèutic de les persones afectades per MPOC de l'ABS Girona 2

L’ús de programes senzills, dirigits a malalts amb MPOC comporta una reducció significativa del nombre de les hospitalitzacions. Amb MPOC com amb qualsevol patologia crònica, és fonamental que tant el pacient com la família rebin una informació adequada sobre la malaltia, els factors de risc, els hàbits que faciliten la progressió i les mesures terapèutiques necessàries en cada moment de la malaltia. És fonamental revisar el compliment del tractament i la tècnicad’inhalació, i els malalts amb insuficiència respiratòria crònica amb tractament d’oxigenoteràpia domiciliària cal revisar els objectius d’aquest tractament, les diferents fonts existents i com utilitzar-les

Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals

Abstract Background HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART with raltegravir reduced CD8 T-cell activation in the Discor-Ral and IntegRal studies, we have evaluated the effect of raltegravir intensification on several soluble inflammation markers in these studies. Methods Longitudinal plasma samples (0–48 weeks) from the IntegRal (n = 67, 22 control and 45 intensified individuals) and the Discor-Ral studies (44 individuals with CD4 T-cell counts<350 cells/µl, 14 control and 30 intensified) were assayed for 25 markers. Mann-Whitney, Wilcoxon, Spearman test and linear mixed models were used for analysis. Results At baseline, different inflammatory markers were strongly associated with HCV co-infection, lower CD4 counts and with cART regimens (being higher in PI-treated individuals), but poorly correlated with detection of markers of residual viral replication. Although raltegravir intensification reduced inflammation in individuals with lower CD4 T-cell counts, no effect of intensification was observed on plasma markers of inflammation in a global analysis. An association was found, however, between reductions in immune activation and plasma levels of the coagulation marker D-dimer, which exclusively decreased in intensified patients on protease inhibitor (PI)-based cART regimens (P = 0.040). Conclusions The inflammatory profile in treated HIV-infected individuals showed a complex association with HCV co-infection, the levels of CD4 T cells and the cART regimen. Raltegravir intensification specifically reduced D-dimer levels in PI-treated patients, highlighting the link between cART composition and residual viral replication; however, raltegravir had little effect on other inflammatory markers.

Role of Myotonic Dystrophy Protein Kinase [DMPK] in Glucose Homeostasis and Muscle Insulin Action

Myotonic dystrophy 1 (DM1) is caused by a CTG expansion in the 3′-unstranslated region of the DMPK gene, which encodes a serine/threonine protein kinase. One of the common clinical features of DM1 patients is insulin resistance, which has been associated with a pathogenic effect of the repeat expansions. Here we show that DMPK itself is a positive modulator of insulin action. DMPK-deficient (dmpk−/−) mice exhibit impaired insulin signaling in muscle tissues but not in adipocytes and liver, tissues in which DMPK is not expressed. Dmpk−/− mice display metabolic derangements such as abnormal glucose tolerance, reduced glucose uptake and impaired insulin-dependent GLUT4 trafficking in muscle. Using DMPK mutants, we show that DMPK is required for a correct intracellular trafficking of insulin and IGF-1 receptors, providing a mechanism to explain the molecular and metabolic phenotype of dmpk−/− mice. Taken together, these findings indicate that reduced DMPK expression may directly influence the onset of insulin-resistance in DM1 patients and point to dmpk as a new candidate gene for susceptibility to type 2-diabetes.

Role of Myotonic Dystrophy Protein Kinase [DMPK] in Glucose Homeostasis and Muscle Insulin Action

Myotonic dystrophy 1 (DM1) is caused by a CTG expansion in the 3′-unstranslated region of the DMPK gene, which encodes a serine/threonine protein kinase. One of the common clinical features of DM1 patients is insulin resistance, which has been associated with a pathogenic effect of the repeat expansions. Here we show that DMPK itself is a positive modulator of insulin action. DMPK-deficient (dmpk−/−) mice exhibit impaired insulin signaling in muscle tissues but not in adipocytes and liver, tissues in which DMPK is not expressed. Dmpk−/− mice display metabolic derangements such as abnormal glucose tolerance, reduced glucose uptake and impaired insulin-dependent GLUT4 trafficking in muscle. Using DMPK mutants, we show that DMPK is required for a correct intracellular trafficking of insulin and IGF-1 receptors, providing a mechanism to explain the molecular and metabolic phenotype of dmpk−/− mice. Taken together, these findings indicate that reduced DMPK expression may directly influence the onset of insulin-resistance in DM1 patients and point to dmpk as a new candidate gene for susceptibility to type 2-diabetes.

Malalties de la civilització

La major part dels habitants de països desenvolupats vivim a grans ciutats, amb una gran densitat de població, entre multitud de persones desconegudes, dependents per a gairebé qualsevol activitat d'una tecnologia que ens fa la vida més fàcil, ens desplacem còmodament en vehicles que ens eviten qualsevol esforç físic i els nostres àpats són abundants. No obstant això, presentem un excés de sucres refinats, sal i greixos i estem totalment desconnectats del medi natural en el qual evolucionem. Estem tan habituats a aquesta vida que, a la majoria no se'ns passa pel cap qüestionar-la i pensem que la nostra manera de viure és la correcta i hauria de ser un model a seguir per qualsevol societat que aspiri a descriure's com a avançada [...]

Anatomia macroscòpica i microscòpica de l'aparell genital femení d'Ophidion barbatum (L.) (Pisces, Ophididae)

S'ha realitzat un estudi de l'anatomia macroscòpica i microscòpica de I'ovari d'Ophidion barbatum (L.) (Pisces, Ophidiidae), utilitzant material recollit per pescadors del port de Blanes (mar català) durant el mes d'octubre de 1985. L'absència d'òrgan copulador en els mascles d'aquesta espècie i la posició de l'orifici nasal anterior, a una certa alçada respecte al llavi superior, ens permet identificar-la com una espècie ovípara, del subordre Ophidioidei, dins de l'ordre Ophidiiformes. L'ovari és únic i continuat caudalment per l'oviducte. Els nombrosos cordons intraovarics que tapien la cavitat augmenten considerablement la superfície germinal. El desenvolupament de l'ovari es correspon amb el tipus asincrònic (Marza, 1938) i la fresa repetida al llarg d'una estació reproductiva més o menys llarga és una estrategia que augmenta la fecunditat, normalment limitada pel volum corporal de la femella. Dins de l'ordre Ophidiiformes, el tipus d'ovari únic sense restes de paret mitjana sembla ser la norma entre les espècies de reproducció ovípara. Aquest fet esta en contradicció amb la teoria de Mendoza (1943) que, fora d'algunes excepcions, l'ovari únic es troba principalment en els teleostis vivípars

10 anys del genoma

Les persones som propenses a celebrar les efemèrides més diverses, unes ocasions que ens haurien de servir per recordar allò que hem fet, veure on som, reflexionar cap a on estem anant i decidir cap a on volem anar. El 26 de juny es van complir 10 anys de l'anunci de l'esborrany del genoma humà, que fou publicat el 15 de febrer de 2001 i completat l'abril del 2003. El dia de l'anunci, el president dels EUA Bill Clinton va dir que "revolucionaria el diagnòstic, la prevenció i el tractament de la major part de malalties humanes, si no de totes". Atesa la rellevància social és un bon moment per fer balanç [...].

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

Background: None of the HIV T-cell vaccine candidates that have reached advanced clinical testing have been able to induce protective T cell immunity. A major reason for these failures may have been suboptimal T cell immunogen designs. Methods: To overcome this problem, we used a novel immunogen design approach that is based on functional T cell response data from more than 1,000 HIV-1 clade B and C infected individuals and which aims to direct the T cell response to the most vulnerable sites of HIV-1. Results: Our approach identified 16 regions in Gag, Pol, Vif and Nef that were relatively conserved and predominantly targeted by individuals with reduced viral loads. These regions formed the basis of the HIVACAT T-cell Immunogen (HTI) sequence which is 529 amino acids in length, includes more than 50 optimally defined CD4+ and CD8+ T-cell epitopes restricted by a wide range of HLA class I and II molecules and covers viral sites where mutations led to a dramatic reduction in viral replicative fitness. In both, C57BL/6 mice and Indian rhesus macaques immunized with an HTI-expressing DNA plasmid (DNA.HTI) induced broad and balanced T-cell responses to several segments within Gag, Pol, and Vif. DNA.HTI induced robust CD4+ and CD8+ T cell responses that were increased by a booster vaccination using modified virus Ankara (MVA.HTI), expanding the DNA.HTI induced response to up to 3.2% IFN-γ T-cells in macaques. HTI-specific T cells showed a central and effector memory phenotype with a significant fraction of the IFN-γ+ CD8+ T cells being Granzyme B+ and able to degranulate (CD107a+). Conclusions: These data demonstrate the immunogenicity of a novel HIV-1 T cell vaccine concept that induced broadly balanced responses to vulnerable sites of HIV-1 while avoiding the induction of responses to potential decoy targets that may divert effective T-cell responses towards variable and less protective viral determinants.

Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals

Antibodies with the ability to block the interaction of HIV-1 envelope glycoprotein (Env) gp120 with CD4, including those overlapping the CD4 binding site (CD4bs antibodies), can protect from infection by HIV-1, and their elicitation may be an interesting goal for any vaccination strategy. To identify gp120/CD4 blocking antibodies in plasma samples from HIV-1 infected individuals we have developed a competitive flow cytometry-based functional assay. In a cohort of treatment-naïve chronically infected patients, we showed that gp120/ CD4 blocking antibodies were frequently elicited (detected in 97% plasma samples) and correlated with binding to trimeric HIV-1 envelope glycoproteins. However, no correlation was observed between functional CD4 binding blockade data and titer of CD4bs antibodies determined by ELISA using resurfaced gp120 proteins. Consistently, plasma samples lacking CD4bs antibodies were able to block the interaction between gp120 and its receptor, indicating that antibodies recognizing other epitopes, such as PGT126 and PG16, can also play the same role. Antibodies blocking CD4 binding increased over time and correlated positively with the capacity of plasma samples to neutralize the laboratory-adapted NL4.3 and BaL virus isolates, suggesting their potential contribution to the neutralizing workforce of plasma in vivo. Determining whether this response can be boosted to achieve broadly neutralizing antibodies may provide valuable information for the design of new strategies aimed to improve the anti-HIV-1 humoral response and to develop a successful HIV- 1 vaccine.